Cavallo F, Di Pierro F, Giovarelli M, Gulino A, Vacca A, Stoppacciaro A, Forni M, Modesti A, Forni G
CNR-Immunogenetics and Histocompatibility Center, University of Turin, Italy.
Cancer Res. 1993 Nov 1;53(21):5067-70.
The potential of interleukin 2-gene-transfected tumor cells to prevent tumor growth and cure established tumors was evaluated using cells from a spontaneous, invasive, and metastasizing mouse mammary adenocarcinoma. Tumor cells engineered to secrete interleukin 2 initially trigger a local inflammatory reaction that leads to inhibition of established parental adenocarcinomas, as well as an antigenically unrelated fibrosarcoma. The ensuing systemic immunity selectively inhibits subsequent parental cell challenges and cures established parental adenocarcinomas and their lung metastases, although less effectively as the neoplastic mass increases. Multiple injections of interleukin 2-gene-transfected tumor cells may thus be considered a new form of vaccination in the management of minimal residual disease and incipient metastases.
使用源自一种自发的、侵袭性的和转移性的小鼠乳腺腺癌的细胞，评估了白细胞介素2基因转染的肿瘤细胞预防肿瘤生长和治愈已形成肿瘤的潜力。经基因工程改造以分泌白细胞介素2的肿瘤细胞最初引发局部炎症反应，该反应导致已形成的亲本腺癌以及抗原性无关的纤维肉瘤受到抑制。随后产生的全身免疫选择性地抑制后续亲本细胞的攻击，并治愈已形成的亲本腺癌及其肺转移灶，尽管随着肿瘤块增大效果会减弱。因此，多次注射白细胞介素2基因转染的肿瘤细胞可被视为在处理微小残留病和早期转移时的一种新型疫苗接种形式。
